Serum pyroglutamyl aminopeptidase activity: a promising novel biomarker candidate for liver cirrhosis

• Published in: Endocrine regulations (Bratislava) Vol. 49; no. 1; p. 20
• Main Authors: Megias, M J, Alba-Araguez, F, Luna, J D, Vives, F, Ramirez-Sanchez, M
• Format: Journal Article
• Language: English
• Published: Germany 01.01.2015
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers - blood; Case-Control Studies; Diagnosis, Differential; Female; Hepatitis - blood; Humans; Liver Cirrhosis - blood; Liver Cirrhosis - diagnosis; Male; Middle Aged; Pancreatitis - blood; Pyroglutamyl-Peptidase I - blood
• ISSN: 1210-0668
• DOI: 10.4149/endo_2015_01_20

As a reflect of tissue damage, serum aminopeptidases have been proposed as biomarkers of various diseases. In order to search new serologic markers for liver cirrhosis we conducted a preliminary study in which we analyzed a broad range of aminopeptidase activities in serum of controls and patients diagnosed with pancreatitis, hepatitis, and liver cirrhosis without distinction among the etiological type or the degree of severity of each condition. Alanyl-, arginyl-, glutamyl-, cystinyl- pyroglutamyl-, and aspartyl-aminopeptidase activities were analyzed fluorometrically, using aminoacyl-β-naphthylamides as substrates. In addition, various parameters, such as alanine transaminase, aspartate transaminase, alkaline phosphatase, total bilirubin, direct bilirubin, and gamma glutamyl transpeptidase were assayed as routine laboratory test for liver function. Compared with control group, alanyl- and arginyl-aminopeptidase activities increased nonspecifically in pancreatitis, hepatitis and liver cirrhosis, glutamyl- and cystinyl-aminopeptidases did not differ between groups and pyroglutamyl-aminopeptidase demonstrated that while pancreatitis and hepatitis did not differ between them and with controls, this activity decreased selectively in liver cirrhosis compared with all the rest of groups (p<0.001 vs. control and p<0.01 vs. pancreatitis and hepatitis). Aspartyl-aminopeptidase also decreased significantly (p<0.05) in liver cirrhosis compared with controls. Routine parameters for liver function test increased, as expected, in the three pathologies analyzed. Despite the heterogeneous composition of the three patient groups, the specific reduction of the levels of pyroglutamyl-aminopeptidase activity in serum of liver cirrhosis patients might be considered as a potential candidate to be included in a combination of markers for the diagnosis of this disease.